Pet Pharm Biotech Co (ROCO:7762) Total Current Liabilities: NT$56.2 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7762 Pet Pharm Biotech Co Ltd ROCO:7762
19 GF Score
Price NT$49.85
! 5 Warning Signs
View Full Analysis

What is Pet Pharm Biotech Co Total Current Liabilities?

Pet Pharm Biotech Co ROCO:7762 +0.20% 19 Total Current Liabilities is NT$56.2 Mil as of Dec. 2025. GuruFocus rates ROCO:7762 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Pet Pharm Biotech Co's total current liabilities for the quarter that ended in Dec. 2025 was NT$56.2

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Pet Pharm Biotech Co Total Current Liabilities Related Terms

Pet Pharm Biotech Co Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Pet Pharm Biotech Co's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pet Pharm Biotech Co Total Current Liabilities Chart

Pet Pharm Biotech Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
19.46 32.31 140.05 56.25

Pet Pharm Biotech Co Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Liabilities Get a 7-Day Free Trial 32.31 135.49 140.05 143.17 56.25
ROCO:7762
19GF Score
Pet Pharm Biotech Co Ltd ROCO:7762
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pet Pharm Biotech Co Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Pet Pharm Biotech Co's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=35.979+14.7
+Other Current Liabilities+Current Deferred Liabilities
=5.57+0
=56.2

Pet Pharm Biotech Co's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=35.979+14.7
+Other Current Liabilities+Current Deferred Liabilities
=5.57+0
=56.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of NT$56.2 Mil mean?
Pet Pharm Biotech Co (ROCO:7762) has a Total Current Liabilities of NT$56.2 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Pet Pharm Biotech Co and its competitors.
Is Pet Pharm Biotech Co's Total Current Liabilities too high?
Pet Pharm Biotech Co's current Total Current Liabilities is NT$56.2 Mil. Overall, Pet Pharm Biotech Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's Total Current Liabilities compare to LLY and JNJ?
Pet Pharm Biotech Co's Total Current Liabilities of NT$56.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Pet Pharm Biotech Co and its competitors. Pet Pharm Biotech Co's current Total Current Liabilities is NT$56.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current Total Current Liabilities of NT$56.2 Mil. The current Total Current Liabilities is NT$56.2 Mil. Pet Pharm Biotech Co's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current Total Current Liabilities is NT$56.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pet Pharm Biotech Co Business Description

Address 143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
19GF Score

Get the complete analysis for ROCO:7762

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$49.85
Price